Arbutus Biopharma Corp
(FRA:I9DN)
€
3.448
-0.098 (-2.76%)
Market Cap: 687.51 Mil
Enterprise Value: 558.40 Mil
PE Ratio: 0
PB Ratio: 5.95
GF Score: 50/100 Arbutus Biopharma Corp at JMP Securities Life Sciences Conference Transcript
May 16, 2023 / 01:00PM GMT
Release Date Price:
€2.3
Roy Buchanan
JMP Securities - Analyst
Happy to kick it off with Arbutus Biopharma here today. They have the whole team with us here. Bill Collier is President and CEO; Mike Sofia, Chief Scientific Officer; and Dave Hastings, Chief Financial Officer. So thanks for joining us, everyone.
Bill Collier
Arbutus Biopharma Corporation - President, CEO, & Director
Thank you.
Dave Hastings
Arbutus Biopharma Corporation - CFO
Thanks, Roy.
Mike Sofia
Arbutus Biopharma Corporation - Chief Scientific Officer
Thanks.
Roy Buchanan
JMP Securities - Analyst
Glad you guys could be here. So pretty exciting year coming up. You guys are developing, obviously, treatments for chronic hepatitis B, trying to get to a functional cure, also coronavirus therapeutics.
Questions & Answers
Roy Buchanan
JMP Securities - Analyst
So let's start off with the chronic hepatitis B. You've got a
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot